Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-23b antagonist
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Anti-miR-23b antagonist refers to a class of antisense oligonucleotides or antagomirs designed to specifically bind and inhibit the function of microRNA-23b (miR-23b). In the context of oncology, particularly renal cell carcinoma, miR-23b has been identified as an oncogenic microRNA (oncomiR) that promotes cell survival and inhibits apoptosis by targeting various tumor-suppressive pathways. By antagonizing miR-23b, these agents aim to restore normal apoptotic signaling and reduce tumor cell viability. Research indicates that high expression of miR-23b correlates with poor survival in renal cancer patients, making it a potential therapeutic target. While primarily used in preclinical research settings to study miRNA function and validate targets, these antagonists represent a broader strategy of miRNA-targeted RNA therapies.
- Other names
- miR-23b inhibitormiR23b inhibitormiR 23b inhibitorantagomir-23bantagomir23bantagomir 23banti-miR-23banti-miR23banti-miR 23b
Beyond the preview
Go deeper on anti-miR-23b antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-23b antagonist.